GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alaunos Therapeutics Inc (NAS:TCRT) » Definitions » Goodwill-to-Asset

TCRT (Alaunos Therapeutics) Goodwill-to-Asset : 0.00 (As of Dec. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Alaunos Therapeutics Goodwill-to-Asset?

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. Alaunos Therapeutics's Goodwill for the quarter that ended in Dec. 2024 was $0.00 Mil. Alaunos Therapeutics's Total Assets for the quarter that ended in Dec. 2024 was $2.76 Mil. Therefore, Alaunos Therapeutics's Goodwill to Asset Ratio for the quarter that ended in Dec. 2024 was 0.00.


Alaunos Therapeutics Goodwill-to-Asset Historical Data

The historical data trend for Alaunos Therapeutics's Goodwill-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alaunos Therapeutics Goodwill-to-Asset Chart

Alaunos Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Goodwill-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Alaunos Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Goodwill-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Alaunos Therapeutics's Goodwill-to-Asset

For the Biotechnology subindustry, Alaunos Therapeutics's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alaunos Therapeutics's Goodwill-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alaunos Therapeutics's Goodwill-to-Asset distribution charts can be found below:

* The bar in red indicates where Alaunos Therapeutics's Goodwill-to-Asset falls into.


;
;

Alaunos Therapeutics Goodwill-to-Asset Calculation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Alaunos Therapeutics's Goodwill to Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Goodwill to Asset (A: Dec. 2024 )=Goodwill/Total Assets
=0/2.755
=0.00

Alaunos Therapeutics's Goodwill to Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

Goodwill to Asset (Q: Dec. 2024 )=Goodwill/Total Assets
=0/2.755
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alaunos Therapeutics  (NAS:TCRT) Goodwill-to-Asset Explanation

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Alaunos Therapeutics Goodwill-to-Asset Related Terms

Thank you for viewing the detailed overview of Alaunos Therapeutics's Goodwill-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Alaunos Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
2617 Bissonnet Street, Suite 225, Houston, TX, USA, 77005
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.
Executives
Boyle Kevin S. Sr. director, officer: Chief Executive Officer C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129
Robert Hofmeister director C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142
Jaime Vieser director ONE FIRST AVENUE, PARRIS BUILDING 34, NAVY YARD PLAZA, BOSTON MA 02129
Robert W Postma director 141 MECOX ROAD, WATER MILL NY 11976
Michael Wong officer: VP, Finance C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BUILDING #34, BOSTON MA 02129
Abhishek K Srivastava officer: See Remarks C/O ALAUNOS THERAPEUTICS, INC., 8030 EL RIO ST., HOUSTON TX 77054
Holger Weis director C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129
Christopher Bowden director 38 SIDNEY STREET, 2ND FLOOR, CAMBRIDGE MA 02139
Mary Thistle director C/O VIACELL, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
James Huang director 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Drew Deniger officer: VP, Research & Development C/O ALAUNOS THERAPEUTICS, INC., 8030 EL RIO ST., HOUSTON TX 77054
Groot Eleanor De officer: EVP, Operations C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129
Melinda Lackey officer: Senior Vice President, Legal C/O ZIOPHARM ONCOLOGY INC., 8030 EL RIO ST, HOUSTON TX 77054
Heidi Hagen director AASTROM BIOSCIENCES, INC., 24 FRANK LLOYD WRIGHT DRIVE, ANN ARBOR MI 48105
Raffaele Baffa officer: Chief Medical Officer C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129

Alaunos Therapeutics Headlines

From GuruFocus

Q2 2021 ZIOPHARM Oncology Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q1 2023 Alaunos Therapeutics Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q3 2019 ZIOPHARM Oncology Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q3 2020 ZIOPHARM Oncology Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q4 2020 ZIOPHARM Oncology Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q3 2022 Alaunos Therapeutics Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q1 2021 ZIOPHARM Oncology Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q2 2020 ZIOPHARM Oncology Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024